Will Bexarotene be a Possible Treatment for Alzheimer's Disease?


Treating cutaneous T-cell lymphoma (CTCL) with a powerful drug that is safe and effective is essential. Bexarotene is a formidable treatment for those patients with CTCL, especially the patients who have found other treatments unsuccessful. Classified as a Retinoid, Bexarotene works to stop the growth of cancer cells. Bexarotene, CAS number 153559-49-0, is also known as the brand name Targretin, from Easai Inc.

Bexarotene has very recently been shown to be a potential opponent in the fight against Alzheimer’s disease. As of February 13th, 2012 Stacy Pagos Haller, President and CEO of the American Health Assistance Foundation (AHAF), announced documented success in studies using bexarotene. These recent studies show a distinct benefit to bexarotene in clearing out the excess plaque found in the Alzheimer’s-disease brains of the mice studied. Not only does bexarotene do this by enhancing the body’s natural defense mechanisms, it also helps to clear amyloid beta proteins, which is a naturally occurring protein in the brain, but is unable to be cleared from the Alzheimer’s diseased brain. This study, done by researchers at Case Western University yields a promising opportunity for future research on mice, as well as human participants. Another boon from this study is that bexarotene is already approved by the FDA and has been for over a decade for cancer treatment. Researchers hope to gain funding from both Congress and The White House for continued trials, as President Obama announced earlier this week that the government will provide an additional $130 million in Alzheimer’s research funding over the next two years. LGM Pharma supplies bexarotene for R&D purposes, and offers assistance to clients through all stages of research.

BexaroteneBexarotene as a treatment for CTCL is taken by the patient once daily, as a capsule, and with food. Side effects most often noted are headache and elevated blood lipid levels. Less often seen side effects include nausea, weakness, chills, abdominal pain and dermatitis.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: